Trial Profile
A Phase III Randomized, Double Blind Placebo Controlled Trial To Evaluate the Non-interference in the Immune Response of Three Doses of ORV 116E to Antigens Contained in Childhood Vaccines and to Assess the Clinical Lot Consistency of Three Production Lots
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs ORV 116E (Primary)
- Indications Rotavirus infections
- Focus Therapeutic Use
- 23 Sep 2016 New trial record